drugset
drugset / Trial / NCT01706835

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

NCT01706835 ↗

Phase 1 Completed 18 enrolled ImmunityBio, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1 open-label study to investigate the pharmacokinetics of aldoxorubicin administered as a 30 minute infustion every 3 weeks for up to 8 cycles in subjects with advanced solid tumors.

Timeline

Start
2012-10
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aldoxorubicin Small molecule 230 mg/m2 Intravenous
Subject Aldoxorubicin Small molecule 350 mg/m2 Intravenous

Indications

cancer